Case Study: Engineering a Cell-Penetrating Peptide Conjugate for CNS-Targeted Antisense Oligonucleotide Delivery

Introduction

Engineering a Cell-Penetrating Peptide Conjugate provides a strategy for the non-invasive delivery of therapeutic antisense oligonucleotides across the blood-brain barrier to address diseases affecting the central nervous system. The blood-brain barrier (BBB) consists of specialized microvascular endothelial cells connected through continuous tight junctions, creating a highly selective barrier that prevents approximately 98% of small-molecule drugs and nearly 100% of large-molecule biopharmaceuticals, including antisense oligonucleotides (ASOs), from entering the central nervous system (CNS). Although ASOs offer the sequence specificity necessary to modify precursor mRNA splicing, suppress pathogenic proteins, or silence mutated genes associated with severe neurodegenerative disorders, their therapeutic application has been constrained by limited systemic bioavailability, rapid renal elimination, and poor membrane permeability. Existing clinical approaches for approved ASO therapeutics, including Nusinersen for spinal muscular atrophy (SMA), therefore rely on repeated intrathecal administration to circumvent the BBB. This invasive approach can result in localized pharmacokinetic fluctuations, procedural and surgical risks, and a considerable burden for patients.

For systemic and non-invasive administration of nucleic acid therapeutics, engineered peptide delivery systems provide a promising means of overcoming structural biological barriers. Cell-penetrating peptides (CPPs), which are generally composed of fewer than 30 amino acids, function as molecular transporters that facilitate the movement of macromolecular cargo across hydrophobic lipid bilayers and endothelial microvasculature. When these peptides are covalently attached to synthetic oligonucleotide analogs, they can enhance cellular internalization, facilitate endosomal escape, and improve tissue penetration into the brain parenchyma after peripheral intravenous administration. This case study presents a comprehensive technical assessment of the biophysical principles, chemical synthesis approaches, bioconjugation architectures, and analytical validation strategies associated with engineering a cell-penetrating peptide conjugate for CNS-directed ASO delivery.

Learn more about How Peptide-Oligonucleotide Conjugates Enter Cells.

Share via:

Quick Summary:

• Cell-penetrating peptide (CPP) conjugates offer a promising non-invasive strategy for delivering antisense oligonucleotides (ASOs) across the blood-brain barrier (BBB) into the CNS.
• CPPs use different BBB-crossing mechanisms, including adsorptive-mediated and receptor-mediated transcytosis. Major classes include cationic, amphipathic, hydrophobic, and receptor-targeted peptides.
• Neutral oligonucleotide backbones such as PMO and PNA improve conjugate stability, solubility, and cellular uptake while reducing charge-driven aggregation associated with conventional negatively charged ASOs.
• Linker engineering is critical for maintaining systemic stability. Ring-opening hydrolysis converts maleimide-thiol adducts into more stable succinamidic acid thioethers (SATE), while SPAAC click chemistry enables precise copper-free conjugation.
• Retro-inverso (RI) peptides using D-amino acids can improve protease resistance and extend plasma exposure while maintaining peptide targeting and biological activity.
• In a preclinical ApoE-BPP8-PMO SMN2 model, receptor-mediated BBB transport achieved approximately 78% brain parenchymal uptake and a 1.25-fold increase in functional SMN protein, demonstrating the potential of systemic CNS delivery.
• Advanced analytical methods, including IP-RPLC, HRMS/LC-MS, ETD/ECD, DLS, and SEC-HPLC, are essential for confirming conjugate identity, stoichiometry, purity, aggregation, stability, and sequence fidelity—supporting the development of reliable CNS-targeted genetic therapeutics.

Biophysical Mechanics in Engineering a Cell-Penetrating Peptide Conjugate for BBB Translocation

Cell-penetrating peptides cross the blood-brain barrier mainly through adsorptive-mediated transcytosis or receptor-mediated transcytosis. These pathways exploit electrostatic interactions arising from positive surface charge or specific receptor-binding interactions to facilitate entry into brain endothelial cells. Through these mechanisms, macromolecular bioconjugates can pass through non-fenestrated microvascular endothelial cells while preserving the integrity of tight junctions and avoiding disruption of the physiological protective properties of the BBB.

Read about Peptide-Oligonucleotide Conjugates in CNS Drug Delivery.

The physicochemical characteristics of an individual peptide sequence strongly influence its cellular entry mechanism as well as its subsequent tissue distribution. Peptides developed for CNS delivery can be grouped into four principal physicochemical classes, with each class relying on different cellular entry pathways:

• Cationic Peptides: Cationic peptides contain high proportions of basic L-arginine and L-lysine residues. Examples include TAT, penetratin, and poly-arginine. These peptides initiate cellular entry through electrostatic interactions with negatively charged heparan sulfate proteoglycans present on the cell surface. The guanidinium headgroups of arginine can establish bidentate hydrogen bonds with membrane phosphate groups, promoting localized membrane invagination and macropinocytosis. Nevertheless, excessively high cationic charge density may increase the risk of non-specific cell lysis and accelerate hepatic clearance.
• Amphipathic Peptides: Amphipathic peptides contain alternating hydrophobic residues, including leucine, isoleucine, and alanine, and hydrophilic residues such as lysine and arginine. These peptides represent more than 40% of identified CPPs. Representative sequences such as Pep-1 and Transportan can adopt amphipathic α-helical or β-sheet conformations after contacting the membrane, thereby supporting direct lipid membrane translocation and facilitating rapid endosomal destabilization.
• Hydrophobic Peptides: Hydrophobic CPPs are derived from signal sequences or viral envelope proteins and include examples such as gH625 and K-FGF. These peptides generally contain a low proportion of charged residues (<20%). Their hydrophobic character enables insertion directly into the lipid bilayer core, allowing translocation through energy-independent passive diffusion mechanisms while maintaining comparatively low cytotoxicity.
• Receptor-Targeting Blood-Brain Barrier Penetrating Peptides (BPPs): To obtain greater CNS selectivity and reduce unwanted accumulation in peripheral tissues, peptides can be engineered to interact with receptor-mediated transcytosis (RMT) pathways. Peptides derived from human apolipoprotein E (ApoE) can target low-density lipoprotein receptor-related protein 1 (LRP1), whereas transferrin receptor-binding peptides, including THR, utilize endothelial endocytic mechanisms to transport attached payloads from the luminal surface toward the brain parenchyma.

Read about Peptide-Oligonucleotide Conjugates in CNS Drug Delivery.

Oligonucleotide Backbone Architectures in Engineering a Cell-Penetrating Peptide Conjugate

Neutral oligonucleotide backbones, including phosphorodiamidate morpholino oligomers and peptide nucleic acids, play an important role in engineering a cell-penetrating peptide conjugate because they minimize electrostatic cross-linking and help maintain conjugate solubility. Replacing negatively charged diester backbones with uncharged linkages reduces intramolecular electrostatic collapse between cationic peptides and oligonucleotides. This approach helps maintain consistent stoichiometry and supports efficient cellular uptake.

Conventional antisense oligonucleotides commonly incorporate phosphorothioate (PS) modifications or 2′-O-(2-methoxyethyl) (2′-MOE) ribose sugars to improve resistance to exonuclease-mediated degradation in plasma. Despite these protective modifications, the overall negative polyanionic character of PS-ASOs creates challenges during bioconjugation. When PS-ASOs are combined with cationic or amphipathic CPPs, electrostatic interactions between the opposing charges can result in uncontrolled complex formation. Such interactions may promote intra- and intermolecular aggregation, precipitation, and variable pharmacokinetic clearance.

To overcome these biophysical incompatibilities, bioconjugation approaches can employ uncharged synthetic nucleic acid mimics:

• Phosphorodiamidate Morpholino Oligomers (PMO): PMOs replace the ribose sugar with a six-membered morpholine ring and replace the charged phosphodiester backbone with an uncharged phosphorodiamidate linkage. PMOs provide strong nuclease resistance, favorable aqueous solubility, and zero net charge. These characteristics permit single-site chemical attachment to CPPs without inducing charge neutralization or promoting self-aggregation.
• Peptide Nucleic Acids (PNA): PNAs contain a synthetic backbone consisting of repeating N-(2-aminoethyl)glycine units connected through peptide amide bonds. Because PNAs are electrostatically neutral, they can form stable Watson-Crick double helices with target mRNA. Their resistance to both nucleases and proteases also provides exceptional biological half-lives.

A fundamental distinction exists between covalent peptide-oligonucleotide bioconjugates and non-covalent complexes. Non-covalent complexation depends on physical electrostatic association and can generate heterogeneous nanoparticle suspensions with inconsistent stoichiometry, limited batch-to-batch reproducibility, and a tendency to dissociate after dilution in systemic circulation. Covalent conjugation, by comparison, produces a single chemically defined molecular entity with a 1:1 stoichiometric molecular weight. This defined architecture supports reliable analytical characterization, predictable circulation kinetics, and more reproducible biological performance.

Compare Conjugation Formats: Read our comparison on Peptide vs. Antibody-Oligonucleotide Conjugates.

Linker Chemistry Optimization and Ring-Opening Hydrolysis in Engineering a Cell-Penetrating Peptide Conjugate

Careful linker engineering, particularly the application of succinimide ring-opening hydrolysis and bioorthogonal click chemistry, plays a central role in controlling the in vivo stability and release characteristics of peptide-oligonucleotide bioconjugates. Stabilization of thiol-maleimide adducts through conversion into succinamidic acid thioethers helps prevent retro-Michael clearance during circulation and preserves the integrity of the conjugate until intracellular delivery occurs.

Read our full guide on Peptide-Oligonucleotide Conjugate Linker Chemistry.

The chemical bond connecting the peptide and oligonucleotide must remain sufficiently stable in the presence of physiological shear stress, serum nucleases, and endogenous plasma thiols. At the same time, the linker should allow suitable payload release or maintain appropriate functional presentation after the conjugate reaches the target neural cells.

Maleimide-Thiol Chemistry and Ring-Opening Hydrolysis

Cysteine-selective maleimide coupling is extensively utilized because of its rapid reaction kinetics and high selectivity. A single engineered cysteine residue on the peptide can react with a maleimide-functionalized ASO terminus to generate a succinimide thioether (SITE) linkage. However, SITE adducts can remain susceptible to retro-Michael exchange reactions in human blood plasma. Endogenous thiols, including human serum albumin (HSA), may displace the maleimide linkage, potentially resulting in detachment of the peptide carrier before the conjugate reaches the BBB.

Retro-Michael exchange can be minimized by subjecting the SITE adduct to controlled ring-opening hydrolysis under mildly alkaline conditions (pH 8.0-8.5). During this process, the succinimide ring is converted into a succinamidic acid thioether (SATE). The resulting SATE structure is more resistant to thiol exchange, increasing the systemic conjugate half-life from hours to more than two years under physiological conditions.

Bioorthogonal Click Chemistry

Strain-Promoted Azide-Alkyne Cycloaddition (SPAAC) is a copper-free click chemistry strategy that involves the reaction between a dibenzocyclooctyne (DBCO) functional group and an azide handle. Because SPAAC does not require copper, it avoids the potential cellular toxicity associated with residual transition metals used in Copper-Catalyzed Azide-Alkyne Cycloaddition (CuAAC). The reaction generates a stable triazole linkage under aqueous conditions while providing high site-specificity.

Proteolytic Stabilization via Retro-Inverso (RI) Peptides

Conventional peptides composed of natural L-amino acids are susceptible to rapid enzymatic degradation by circulating endo- and exopeptidases. In a Retro-Inverso modification, the peptide sequence is synthesized in reverse order using D-amino acids. This configuration preserves the topological orientation of side chains required for receptor recognition while making the peptide backbone resistant to enzymatic cleavage. Bioconjugates containing RI-modified peptides consequently exhibit substantially prolonged plasma half-lives while retaining their biological targeting capabilities.

Read our breakdown of Peptide-Oligonucleotide Conjugate Stability.

Preclinical Quantitative Case Study: Engineering a Cell-Penetrating Peptide Conjugate for SMN2 Modulation

Preclinical investigations involving apolipoprotein E-derived peptide-PMO conjugates have demonstrated that systemic administration can result in 78% of the bioconjugate reaching the brain parenchyma and can produce a 1.25-fold elevation in functional SMN2 protein. This quantitative case study illustrates how receptor-targeted peptide conjugation can transform otherwise poorly permeable nucleic acid therapeutics into systemically active CNS-directed treatments.

In an experimental model of spinal muscular atrophy (SMA), blood-brain barrier-penetrating peptides derived from the receptor-binding region of apolipoprotein E (ApoE-BPPs) were conjugated to phosphorodiamidate morpholino oligomers (PMO) designed to target the SMN2 gene. The therapeutic objective was to alter pre-mRNA splicing and enhance exon 7 inclusion, thereby promoting production of functional, full-length SMN protein within central motor neurons.

Attachment of the ApoE-derived peptide BPP8 to a neutral PMO payload through a stable covalent linker allowed the resulting conjugate to interact with low-density lipoprotein receptor-related protein 1 (LRP1) expressed on microvascular endothelial cells following intravenous administration. Quantitative fluorescence imaging using Cy7-labeled BPP8-PMO constructs demonstrated that 78% of the systemically administered dose crossed the blood-brain barrier and entered the brain parenchyma, while 11% achieved direct neuronal uptake.

Pharmacodynamic analysis demonstrated a concentration-dependent elevation in full-length SMN2 mRNA transcripts, resulting in a 1.25-fold increase in functional SMN protein throughout brain and spinal cord tissues compared with unconjugated PMO control groups. In addition, substitution of the L-amino acid peptide with a retro-inverso D-amino acid counterpart (RI-BPP8-PMO) maintained splicing activity while extending the circulating plasma half-life. These findings demonstrate that engineering the peptide backbone can directly improve systemic CNS delivery.

Explore Peptide-Oligonucleotide Conjugate Pharmacokinetics.

Analytical Quality Control Protocols for Engineering a Cell-Penetrating Peptide Conjugate

Comprehensive characterization of peptide-oligonucleotide bioconjugates depends on ion-pair reversed-phase liquid chromatography combined with high-resolution mass spectrometry to establish accurate stoichiometry, sequence fidelity, and product purity. These analytical workflows provide confirmation of construct identity and stability while supporting stringent bioanalytical quality requirements.

Learn about Sequence Confirmation Strategies for Peptide-Oligonucleotide Conjugates.

Because peptide-oligonucleotide conjugates incorporate hydrophobic peptide sequences together with hydrophilic, multi-charged nucleic acid components, their characterization requires carefully designed separation and mass spectrometry workflows:

• Chromatographic Separation Methods: Ion-Pair Reversed-Phase Liquid Chromatography (IP-RPLC), using triethylammonium acetate (TEAA) or hexylamine as volatile ion-pairing agents, can effectively separate unreacted peptides, unconjugated oligonucleotides, and the desired bioconjugates. Hydrophilic Interaction Liquid Chromatography (HILIC) offers an orthogonal separation approach for resolving hydrophilic impurities, charge variants, and degradation products.
• High-Resolution Mass Spectrometry (HRMS): Electrospray Ionization LC-MS (ESI-LC-MS) and Matrix-Assisted Laser Desorption/Ionization Time-of-Flight (MALDI-TOF) MS can be used to establish exact molecular mass and assess product purity. Soft ionization tandem mass spectrometry using Electron Transfer Dissociation (ETD) or Electron Capture Dissociation (ECD) enables fragmentation of the bioconjugate backbone while preserving labile chemical linkers. This approach supports detailed verification of both amino acid and nucleotide sequences.
• Physicochemical and Stability Testing: Dynamic Light Scattering (DLS) and Size Exclusion Chromatography (SEC-HPLC) are applied to characterize solution-phase aggregation profiles. For formulations intended for lyophilization, cryoprotectants such as sucrose or trehalose can be combined with non-ionic surfactants to support long-term structural stability and reduce oxidative degradation during storage.

Explore techniques for Structural Characterization of Peptide-Oligonucleotide Conjugates.

Conclusion

Engineering a Cell-Penetrating Peptide Conjugate provides a non-invasive approach for transporting genetic therapeutics across the blood-brain barrier and into central nervous system tissues. By combining receptor-targeted peptide sequences, uncharged nucleic acid backbones, and chemically stabilized linkers, including ring-opened succinamidic acid thioethers, bioconjugate platforms can address major barriers associated with systemic delivery and enable targeted gene modulation. Findings from ApoE-derived peptide-PMO studies indicate that systemic administration can transport bioconjugates into the brain parenchyma and promote restoration of target gene splicing, providing a potential alternative to invasive intrathecal administration. As advanced analytical techniques, including high-resolution IP-RPLC and tandem LC-MS, continue to improve characterization and quality control workflows, engineered peptide-oligonucleotide conjugates have the potential to support the clinical translation of targeted genetic medicines for complex neurological conditions.

To consult with bioconjugate specialists and explore custom analytical characterization services, visit the ResolveMass Laboratories Contact Page.

Frequently Asked Questions

Reference:

1. Zou, L.-L., Ma, J.-L., Wang, T., Yang, T.-B., & Liu, C.-B. (2013). Cell-penetrating peptide-mediated therapeutic molecule delivery into the central nervous system. Current Neuropharmacology, 11(2), 197–208. https://doi.org/10.2174/1570159X11311020006
2. Leckie, J., & Yokota, T. (2024). Potential of cell-penetrating peptide-conjugated antisense oligonucleotides for the treatment of SMA. Molecules, 29(11), 2658. https://doi.org/10.3390/molecules29112658
3. Boisguérin, P., Deshayes, S., Gait, M. J., O’Donovan, L., Godfrey, C., Betts, C. A., Wood, M. J. A., & Lebleu, B. (2015). Delivery of therapeutic oligonucleotides with cell penetrating peptides. Advanced Drug Delivery Reviews, 87, 52–67. https://doi.org/10.1016/j.addr.2015.02.008
4. Yeoh, Y. Q., Amin, A., Cuic, B., Tomas, D., Turner, B. J., & Shabanpoor, F. (2024). Efficient systemic CNS delivery of a therapeutic antisense oligonucleotide with a blood-brain barrier-penetrating ApoE-derived peptide. Biomedicine & Pharmacotherapy, 175, 116737. https://doi.org/10.1016/j.biopha.2024.116737
5. Boado, R. J. (1995). Antisense drug delivery through the blood-brain barrier. Advanced Drug Delivery Reviews, 15(1–3), 73–107. https://doi.org/10.1016/0169-409X(95)00006-S
6. Hammond, S. M., Abendroth, F., Gait, M. J., & Wood, M. J. A. (2019). Evaluation of cell-penetrating peptide delivery of antisense oligonucleotides for therapeutic efficacy in spinal muscular atrophy. Methods in Molecular Biology, 2036, 221–236. https://doi.org/10.1007/978-1-4939-9670-4_13

Get In Touch With Us

About The Author

Anusha Sinha